Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bairese Wan for stable vitiligo (Phase II, randomized, double-blind, placebo-controlled)
CTR20231099Phase 2Completed
- Sponsor
- Xinjiang Uygur Autonomous Region Institute of Uygur Medicine
- Start
- Apr 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Baireisi Pill in Vitiligo (2 arms), sponsored by Xinjiang Uygur Autonomous Region Institute of Uygur Medicine. Primary endpoint: Proportion of subjects with >50% improvement in VASI at main evaluation lesion at week 24. Started Apr 2023; status: completed.
02
Drugs
Baireisi Pill
03
Conditions
Vitiligo
Beyond the preview
Go deeper on CTR20231099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231099.